Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

21. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908; Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2010;362(22):2077–2091; Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurology. 2009;8(1):67–81; Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. New England Journal of Medicine. 2001;345(13):956–963; Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73; Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Archives of Neurology. 2011;68(2):165.

22. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology. 2019;15(4):234–242.

23. Medtronic Activa Tremor Control System. US Food and Drug Administration. Premarket Approval (PMA). www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P960009. Updated March 25,

2019. Accessed March 29, 2019.

24. Rossi PJ, Giordano J, Okun MS. The problem of funding off-label deep brain stimulation: bait-and-switch tactics and the need for policy reform. JAMA Neurology. 2017;74(1):9-10; Abosch A, Timmermann L, Bartley S, et al. An international survey of deep brain stimulation procedural steps. Stereotactic and Functional Neurosurgery. 2013;91(1):1-11.

25. Eberle W, Penders J, Yazicioglu RF. Closing the loop for deep brain stimulation implants enables personalized healthcare for Parkinson’s disease patients. Paper presented at the 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, August 30-September 3, 2011; Patel S, Mancinelli C, Hughes R, Dalton A, Shih L, Bonato P. Optimizing deep brain stimulation settings using wearable sensing technology. Paper presented at the 2009 4th International IEEE/EMBS Conference on Neural Engineering, April 29May 2, 2009.

26. Anidi C, O’Day JJ, Anderson RW, et al. Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson’s disease. Neurobiology of Disease. 2018;120:107–117; Malekmohammadi M, Herron J, Velisar A, et al. Kinematic adaptive deep brain stimulation for resting tremor in Parkinson’s disease. Movement Disorders. 2016;31(3):426–428.

27. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99-107.

28. Henderson R. The purple membrane from Halobacterium halobium. Annual Review of Biophysics and Bioengineering. 1977;6:87-109.

29. Там же.

30. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99-107.

31. Там же.; Fenno L, Yizhar O, Deisseroth K. The development and application of optogenetics. Annual Review of Neuroscience. 2011;34(1):389–412.

32. Kravitz AV, Freeze BS, Parker PRL, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622–626.

33. Там же.

34. Там же.

35. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;360(6384):36–37.

36. Там же.

37. Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for Parkinson’s disease. Denali Therapeutics. August 1, 2018. http://investors.denalitherapeutics. com/ news-releases/ news-release-details/denali-therapeutics-announces-positive-clinical-results-lrrk2#ir-pages. Accessed November 29, 2018.

38. Denali Therapeutics announces first patient dosed in phase 1B study of DNL201 for Parkinson’s disease [пресс-релиз]. Denali Therapeutics, December 10, 2018; Study to evaluate DNL201 in subjects with Parkinson’s disease. US National Library of Medicine: ClinicalTrials. gov. https://clinicaltrials.gov/ct2/show/NCT03710707. Updated March 28, 2019. Accessed March 29, 2019.